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High-throughput drug screening in live 
cells is widely used in fundamental research 
and drug discovery.[1] More than half of the 
small-molecule drugs approved in the last 
decade were discovered using phenotypic 
cell-based assays.[2] Herein, cells are used 
as simplified disease models that are incu-
bated with compounds in vitro to search for 
desirable cellular phenotypes. Any drug-
like compound can interfere with multiple 
cellular processes, including cell signaling, 
metabolism, protein expression, secretion, 
progression of the cell cycle or cell death.[3] 
Complementing phenotypic assays, mecha-
nistic cell-based assays measure pharmaco-
dynamic (PD) markers in cells, either alone 
or in small combinations, which indicate 
how a compound penetrates the cell and 
how it engages a defined pharmacological 
target. The most common methods for 
detecting such changes include microscopy, 
bulk solution assays, or off-line bioanalytic 
assays.[4] These methods usually require 
specific labels to quantify the change in cell 
phenotype, or multistep biochemical work-
ups to quantify the PD biomarker. With microscopy-based read-
outs, specific antibodies or special dyes are commonly used to 
visualize different cell processes; for example, propidium iodide 
staining is used to assess apoptosis, calcein staining is used to 
estimate cell viability, and anti-Ki67 antibody labeling is used to 
assess cell proliferation.[5] PD drug responses can be monitored 
by changes in biomolecular cell composition. Label-free readout 
methods can enable an unprecedented view of how drug treat-
ment affects the composition and modification of cellular bio-
molecules beyond expected target molecules.
Many label-free analytic technologies lack the molecular speci-
ficity (e.g., spectroscopic methods), the speed required for high-
throughput cell assays, or they are not able to be used in matrices 
as complex as cells (e.g., nuclear magnetic resonance or surface 
plasmon resonance). Chemical sensors and artificial receptors, 
such as cyclodextrins or cucurbiturils, can only be applied to spe-
cific analytes. Moreover, apart from spectroscopic methods, none 
of these techniques allow spatial probing of a single cell culture—
something that is important due to heterogeneous cell responses 
and cell-to-cell variation and, which is necessary to predict the phar-
macological ability of compounds to tackle unmet medical needs.[6]
In pharmaceutical research and development, cell-based assays are 
primarily used with readout that rely on fluorescence-based and other 
label-dependent techniques for analysis of different cellular processes. Supe-
rhydrophobic–hydrophilic droplet microarrays (DMA) and matrix-assisted 
laser desorption/ionization (MALDI) mass spectrometry (MS) have recently 
emerged as key technologies for miniaturized high-throughput cell assays 
and for label-free molecular high-content drug profiling, respectively. Here, 
nanoliter-scale cell assays are integrated on DMAs with MALDI–MS imaging 
(MALDI–MSI) approaches to a droplet microarray–mass spectrometry 
imaging (DMA–MSI) platform. Using A549 lung cancer cells, concentration-
response profiling of a pharmaceutical compound, the fatty acid synthase 
inhibitor GSK2194069, are demonstrated. Direct cell culture on DMAs 
enables combination of microscopy and high speed, high molecular content 
analysis using MALDI–MSI. Miniaturization of array spots down to 0.5 mm 
confining 40 nL droplets allows for MALDI imaging analysis of as few as 
ten cells per spot. Partial automation ensures a fast sample preparation 
workflow. Taken together, the integrated DMA–MSI platform that combines 
MALDI-MSI, as a label-free analytical readout, with the miniaturized droplet 
microarray platform is a valuable complement to high throughput cell-based 
assays technologies.
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Matrix-assisted laser desorption/ionization (MALDI) mass 
spectrometry (MS) is fast, compatible with high-throughput 
screening, reasonably quantitative, covers a variety of biomo-
lecular classes and, through MS imaging (MSI), supports spa-
tially resolved analysis down to a single cell within a popula-
tion. In recent years, MALDI–MS has emerged as a leading 
analytical tool in cell-based drug discovery and profiling.[7–12] 
It is a versatile technology for the label-free analysis of various 
classes of molecules, and is fast becoming established as a 
high-throughput method for biochemical screening assays.[12–14] 
In non-pharmacological applications, the utility of MALDI–
MS for single cell metabolite analysis has been demonstrated, 
including in microcavity arrays.[15–17] Compared with commonly 
used fluorescence- and chemiluminescence-based readouts, 
which require costly and non-physiological secondary probes 
and therefore suffer from false-positive and false-negative 
results,[14] MALDI–MS is label-free and allows multiple compo-
nents to be detected simultaneously.[12]
Recently, MALDI–MS has also been adopted to analyze 
changes in the biomolecular composition of whole cells—both 
microbial,[18] and mammalian[7,9,12,19]—after treatment with 
putative therapeutic compounds. Since hundreds of molecules 
can be detected simultaneously, MALDI–MS can identify PD 
effects in cells at the lipid or metabolic level using compu-
tational workflows.[10] Concentration-dependent molecular 
changes can be measured for known and directly affected abun-
dant proteins (e.g., polyacetylated histones), or for low mole-
cular mass PD markers in mammalian cells.[7,9,19] For example, 
to profile cellular levels of potential fatty acid synthase (FASN) 
in K562 cells, MALDI–MS has been used to determine the 
accumulation of malonyl-coenzyme A (CoA), the substrate of 
FASN.[9]
MALDI–MS can detect multiple analytes in parallel and in 
a high throughput manner. This makes it an attractive candi-
date for adaptation to a label-free detection method in high-
throughput screening applications. However, one drawback is 
that the multi-well plates commonly used for biochemical and 
cell-based assays, which provide separated reservoirs for mul-
tiple single biological experiments in parallel, cannot be used 
for MALDI–MS directly. This is because they are incompatible 
with lasers, and are made from non-conductive polystyrene; for 
high ion yield and strong signal readout, an appropriate con-
ductive substrate must be chosen.[20] Therefore, if MALDI–MS 
is to be used in a high throughput context, analytes or cells 
must be transferred from multi-well plates onto special MALDI 
plates, or onto microarrays for mass spectrometry.[7,9,12–15,17,19] 
This step can be automated for measuring analytes in solution, 
but cannot be done to detect the biomolecules of intact treated 
cells directly on the platform.[14]
Recently, we developed a miniaturized cell screening platform 
based on arrays of sub-100  nL droplets. These are formed in 
0.5–3.0  mm hydrophilic spots, separated by superhydrophobic 
regions.[21,22] Such “droplet microarrays” allow drug screening to 
be conducted in up to 1000-fold lower volumes, with proportion-
ally lower quantities of reagents and cells. This not only reduces 
the cost of drug screening, but also helps to enables disease-
relevant screening of rare and primary cells, such as stem cells 
and patient-derived cells. This ground breaking experimental 
approach has great potential for diverse applications, including 
combination of chemical synthesis and biological screening, as 
well as various readout formats and analytics approaches.
Until now, droplet microarray cell screening has been per-
formed using established fluorescence microscopy readouts. 
In this study, we present a novel MALDI-on-a-chip platform 
called Droplet Microarray–Mass Spectrometry Imaging (DMA–
MSI). The DMA–MSI platform enables cell-based compound 
profiling or screening in droplets in nanoliter- or microliter 
scale volumes. This is, followed by microscopy and consequent 
measurement of PD markers by MALDI–MSI directly on the 
array, without the need to transfer cells to a specialized MALDI 
plate. We demonstrate the feasibility of our new platform for 
monitoring the intracellular accumulation of malonyl-CoA in 
A549 cells, in response to the selective, small FASN inhibitor 
GSK2194069. This approach enables highly miniaturized, cell-
based, high-throughput assays combined with both optical and 
sensitive label-free MSI readouts on a chip. The DMA–MSI 
platform reveals new opportunities to monitor pharmacody-
namics in live cells, which is crucial for drug discovery and pre-
cision medicine.
2. Results and Discussion
We have developed the versatile DMA–MSI platform, which 
combines a droplet microarray (DMA) platform for the high-
throughput screening of live cells, with MALDI–MS imaging 
for label-free pharmaceutical bioanalysis of cells on a single 
array. In Figure  1, the rapid work-flow from customized array 
manufacturing, cell culture on array, sample preparation, meas-
urement and data analysis are shown. Droplet micro arrays 
are planar, wall-less arrays of hydrophilic spots in a superhy-
drophobic background, which enable dense arrays of stable, 
separated droplets to be formed in the order of nanoliter to 
microliter volumes. Advantages of the DMA platform for cell 
screening include its high-throughput ability (80–4500 spots 
per microscope glass slide), miniaturized format (up to 103-fold 
reduction in reagent and cell volume), versatility (compatibility 
with all types of cells and 2D and 3D cell culture models), and 
compatibility with existing high-content screening workflows 
based on microscopy-based readouts.[22,23] Its planarity and 
ability to confine low volumes in defined areas also offer unique 
features crucial for MALDI-MS imaging. Therefore, DMA com-
bines advantages for screening live cells and MALDI-MS anal-
ysis, making it possible to perform both on the same platform.
2.1. Preparation of DMA-ITO Slides
As a first step, we have established DMAs on a conductive 
surface, which is necessary for MALDI–MSI. DMAs were pre-
pared on transparent indium tin oxide (ITO)-coated slides. 
The coating renders the surface conductive, with a resistance 
of 150–170 Ω sq−1; this is important to be able to achieve high-
sensitivity MALDI–MSI measurements in high-vacuum ion 
sources. To evaluate the ability to miniaturize the DMA–ITO 
slides, we prepared DMA–ITO slides with spots of different 
sizes: 3, 1, and 0.5 mm. The receding water contact angle was 
close to 0 and hard to measure owing to high hydrophilicity. 
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The background of the array was shown to be superhydrophobic 
with static water contact angle and sliding angles being 160° 
and 5.3 ± 2.2, respectively. Such a large difference in hydrophi-
licity is important to confine cell suspensions or MALDI matrix 
solutions with different volumes to hydrophilic spots.
2.2. MALDI–MSI Optimization
To test the effect of surface patterning on MALDI–MS analysis, 
we first added 5  µL of cell culture medium to 3  mm hydro-
philic spots. Unlike non-patterned ITO, the DMA–ITO slides 
ensured uniform, compact and constant droplets of cell cul-
ture medium; this is a prerequisite for successful cell culture, 
especially in miniaturized nanoliter (spot size <  1  mm)  for-
mats (Figure  2A). Indeed, the ability to create liquid droplets 
with footprints of defined geometry and size was shown to be 
important for the crystallization of 2,5-dihydroxybenzoic acid 
(DHB) matrix, whether alone or in dried droplet mixtures with 
a brain lipid extract. In this study, homogeneously distributed 
matrix-analyte co-crystals were formed on DMA–ITO rather 
than matrix crystallization from droplets on non-patterned 
ITO slides (Figure  2B). This improved matrix crystallization 
was found to be important to enhance homogeneity of the MS 
signals; for example, the exemplary peak at m/z 760.6, which 
presumably corresponds to the protonated abundant mem-
brane phospholipid phosphatidylcholine (PC, 34:1) across the 
spots (Figure 2C). Several studies have noted the importance of 
uniform, homogeneous spots in MALDI–MS assays.[10,11,24] It is 
well known that DHB matrix can form inhomogeneous spots, 
with greatly varying intensities of analyte ions across the spot. 
This has prompted some authors to stop using it in assays, and 
others to employ matrix sprayers to prepare samples by spray-
coating rather than dried droplets.[10,11]
We also compared the intensity of MS signals, and sensi-
tivity of the measurements to evaluate total brain lipid extracts 
co-crystallized with DHB matrix on functionalized versus non-
functionalized ITO slides (Figure S1, Supporting Information). 
The results demonstrated no reduction in MS sensitivity, which 
might otherwise occur because of the potential for the addi-
tional coating to create superhydrophobic–hydrophilic patterns 
insulating the underlying conductive substrate. Therefore, we 
demonstrated that better confinement of analytes and improved 
homogeneity of matrix crystallization on DMA–ITO slides are 
possible, compared with standard ITO slides, with no loss of 
sensitivity in MS measurements.
2.3. Cell Culture on DMA–ITO Slides
To test the biocompatibility of the patterned ITO slides, we cul-
tured A549 lung cancer cells in 5 µL, 150 nL, and 40 nL droplets, 
confined in 3, 1, and 0.5  mm hydrophilic spots, respectively. 
Using a non-contact liquid dispenser, the cells were dispensed 
directly onto the hydrophilic spots, which allowed droplet 
volume control down to a few nanoliters, as well as control of 
the number of cells per spot by adjusting printing volumes and 
cell concentration. Initially, we used a constant cell density of 
Figure 1. Integration of DMA–ITO Slides and MALDI–TOF–MSI to a Technology Platform for Label-free Cell-based Assays. Combining miniaturized 
high-throughput cell screening based on droplet microarrays (DMA) on conductive indium tin oxide (ITO) glass slides, with high-content bioanalysis 
using matrix-assisted laser desorption/ionization–time-of-flight–mass spectrometry imaging (MALDI–TOF–MSI) enables cell-based assays for cell and 
drug screening. The platform enables direct cell culture on DMA–ITO slides, cell treatment and the possibility to perform microscopy applications 
as well as MALDI–TOF–MSI analyses. The workflow includes: a) ITO slide patterning to create an array of hydrophilic spots on a superhydrophobic 
surfaces; b) seeding and culturing cells in nanoliter droplets on the chip, followed by microscopy readout; c) application of MALDI matrix, and d) 
MALDI-MS imaging of cells in each hydrophilic spot, followed by data analysis.
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141 cells mm−2, (corresponding to 1000, 111 and 28 cells per array 
spot on 3, 1, and 0.5  mm DMA, respectively). Cells were cul-
tured on the DMA–ITO slides for 18 h in a humidity chamber, 
which was placed in a regular cell culture incubator. To evaluate 
their viability, cells were stained with calcein (indicating viable 
cells) and propidium iodide (PI, an indicator of dead cells) by 
printing corresponding reagents directly into the spots. As 
judged by fluorescence microscopy imaging, the viability of all 
tested culture volumes and cell densities was above 90%. This 
demonstrates good biocompatibility of the novel DMA–ITO 
slides, and the possibility to greatly miniaturize cell experi-
ments using 0.5 mm spots and 40 nL droplets (Figure 3A). Cell 
viability remained above 90% at higher (707  cells mm−2, cor-
responding to 5000, 555, and 138  cells per array spot on 3, 1, 
and 0.5  mm DMAs, respectively) and lower cell densities 
(14  cells mm−2, corresponding to 100, 11, and 3  cells per array 
spot on 3, 1, and 0.5 mm DMAs, respectively) (Figure 3D).
2.4. MALDI–MSI of Whole Cells Cultured Using DMA-ITO 
Slides
Next, we investigated the possibility of combining miniatur-
ized cell experiments using 5 µL to 40 nL droplets formed on a 
Figure 2. Features of Microstructured ITO Slides Compared with Conventional Usage of ITO Slides for Spatially Resolved MALDI–MS Imaging. A) 
Droplet microarray–indium tin oxide (DMA–ITO) slides ensure that cell culture media form uniform, compact, constant droplets. B) Efficient matrix/
analyte co-crystallization caused by compact and stationary droplet formation on DMA–ITO, which leads to consistent distribution of ion intensities. 
C) Exemplary total ion count (TIC)-normalized matrix-assisted laser desorption/ionization–mass spectrometry (MALDI–MS) ion image showing the 
spatially resolved lipid distribution of m/z 760.6, presumably corresponding to the protonated phosphatidylcholine (PC, 34:1). D) Signal intensities of 
TIC-normalized mean spectra extracted from regions of interest (ROI) from ITO (blue) versus DMA–ITO (green) are comparable. No additional m/z 
peaks were detected owing to the nanorough coating. Data processing was carried out using SCiLS Lab, and TIC-normalized mean spectra of ROI 
drawn in SCiLS Lab were exported into mMass, in order to flip spectra vertically to detect possible differences.
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Figure 3. Miniaturized A549 Cancer Cell Culture on Different DMA–ITO Formats. A) Proportional down-scaling of cell number per array spot on 
3, 1, and 0.5 mm droplet microarray–indium tin oxide (DMA–ITO). Shown are droplet array size, shape, and corresponding cell numbers per spot. 
Demonstration of biocompatibility for cells cultured on DMA–ITO. Cell viability testing (calcein staining; green) after cultivation overnight showed 
>90% viable cells and lack of toxicity (dead cell indicator propidium iodide (PI); red) resulting from photochemical microstructuring on ITO glass. B) 
To analyze miniaturized cell cultures, A549 cells were seeded at different cell numbers per spot, representing constant cell densities (cells/mm2) to 
study the various DMA–ITO spot sizes (3, 1, 0.5 mm). Spatial segmentation by bisecting k-means clustering with k = 2 of matrix-assisted laser des-
orption/ionization–mass spectrometry imaging (MALDI–MSI) datasets acquired on differently sized DMA–ITO cell arrays distinguishes cell-bearing 
pixels (green) from matrix background (red) down to nearly the single-cell level. Data processing and unsupervised segmentation analysis was carried 
out using SCiLS Lab and results are shown for (n = 6) six technical replicates for each array size. C) Corresponding MALDI–MSI ion images show the 
spatial signal distribution of m/z 760.6, tentatively assigned to the protonated cell membrane lipid phosphatidylcholine (PC, 34:1) for the highest and 
lowest cell density seeded out on different array sizes. MSI data were acquired using a raster width of 50 µm for the 3 mm slides, and 25 µm for the 1 
and 0.5 mm DMA–ITO slides, respectively. D) Shows over 90% cell viability monitored prior to MALDI–MSI measurements shown in (B) after overnight 
cell culture on DMA–ITO. Data were presented as mean ± standard deviation (n = 3 technical replicates out of datasets from (B). E) Original total ion 
count (TIC)-normalized spectra of m/z 760.6 from a signal-bearing pixel extracted from the respective array positions, with the lowest cell number per 
spot for the different array sizes were analyzed using the mMass open source mass spectrometry tool. Shown are means ± standard deviation (SD) of 
three (n = 3) technical replicates from the dataset in (B).
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DMA–ITO slide with chemical analysis using MALDI–MSI on 
the same slide. A549 cells were cultured on DMA–ITO slides 
with different hydrophilic–superhydrophobic patterns to form 
arrays of 5 µL, 150 nL and 40 nL droplets. The initial cell den-
sity varied from 14 cells/mm2 to 707 cells/mm2 (corresponding 
to seeded cell numbers indicated in Table 1 and Figure 3B) to 
investigate different cell culture conditions. The viability of 
cells on DMA–ITO slides was confirmed by live/dead staining 
using fluorescence microscopy. Then, the same DMA slide was 
washed with ice-cold ammonium formate and air-dried slides 
were spray-coated with 60  mg/mL DHB matrix in in ACN/
ddH2O/TFA (50/49.9/0.1; v/v/v), followed by MALDI–MSI 
analysis in a RapifleX MALDI–TOF mass spectrometer. MSI 
data were acquired using a raster width of 50 µm for the 3 mm 
DMA slides, and 25 µm for the 1 mm and 0.5 mm DMA slides. 
Computational analysis of MALDI–MSI data was performed 
using SCiLS Lab software, using the spatial segmentation map 
generated by bisecting k-means clustering. Employing k = 2 for 
the clustering, cell-bearing and non-cell-bearing pixels could 
conveniently be distinguished down to <10 cells per array spot 
(Figure  3B). Corresponding MALDI–MSI ion images show 
the spatial signal distribution of the abundant cell membrane 
lipid (presumably PC 34:1; m/z 760.6; normalized to total ion 
current) for the highest and lowest cell density seeded out on 
different array sizes (Figure 3C). This indicates that cell mem-
brane lipids can be detected and visualized on DMA–ITO 
slides down to single cell numbers. The spatial distribution of 
analytes of interest was visualized as ion intensity maps using 
SCiLS Lab software, which revealed the possibility of single cell 
imaging. The cell patterns formed by cells cultured inside drop-
lets is clearly visible. Ion intensity of m/z 760.6 was similar for 
various given cell densities, independent of the DMA format (3, 
1, or 0.5 mm; Figure S2, Supporting Information). These results 
demonstrate that MALDI–MSI readout has potential sensitivity 
down to the single cell level. Combined with parallel optical 
microscopy readouts, high-throughput screenings and extreme 
miniaturization, this shows the unique potential for MALDI-MS 
imaging on the same platform as droplet microarray technology.
2.5. Quantitative Assessment of Biomarkers Using DMA–MSI 
Platform
GSK2194069 was chosen to demonstrate the possibility of using 
the DMA–MSI platform to functionally and quantitatively inves-
tigate PD biomarker changes in response to small molecule 
drug-like compounds. GSK194069 is a selective fatty acid syn-
thase (FASN) inhibitor, which leads to intracellular accumula-
tion of the FASN substrate (and acetyl-CoA-carboxylase product) 
malonyl-CoA (Figure 4A), as demonstrated and analytically vali-
dated in a MALDI cell assay using steel targets.[9] To this end, 
A549 cells were cultured in 3 mm spots on an DMA–ITO slide 
for 18 h, then treated for 24 h in the presence of GSK2194069. 
This was followed by a spray-coat with MALDI matrix and anal-
ysis by MALDI–MSI directly on the slide. MALDI–TOF mass 
spectra were normalized to the total ion count (TIC). Upon 
GSK20194069 treatment, the lung cancer cells displayed sub-
stantially increased ion intensities of m/z 854.1. Weigt et al. had 
previously validated this m/z as malonyl-CoA using MALDI-
FT-ICR-based accurate mass determination and tandem-MS 
experimentation.[9] The data indicate intracellular accumulation 
of malonyl-CoA in response to FASN inhibition (Figure 4B–D).
Due to the high costs of compounds and large reagent vol-
umes (microliters), high-throughput cell screening experi-
ments are usually performed using only a single compound 
concentration. On the contrary, the droplet microarray plat-
form requires only nanoliters, thereby reducing the overall 
screening costs. Small volumes also allow more than one 
drug concentration to be tested in a high-throughput manner, 
making IC50 curves a possible outcome of cell-based screening. 
Multiple repetitions are also more plausible, inevitably leading 
to a better reproducibility and reliability of the observed 
results.[9,25] The compatibility of DMA slides with MALDI–MSI 
allows IC50 curves to be constructed using chemical informa-
tion obtained by mass-spectrometry. To demonstrate this con-
cept, we analyzed drug responses in A549 cancer cells on the 
DMA–MSI platform. Adherent-grown cells were incubated 
for 24 h on 3 mm array spots in the presence of different con-
centrations of the FASN inhibitor GSK2194069, followed by 
washing the DMA–ITO slide three times with ice-cold 150-mm 
ammonium formate at pH  7.4. After air-drying, the slide was 
spray-coated with DHB matrix. Concentration-response curves 
of two TIC-normalized peaks ([M+H]+ m/z 854.1 and 760.6) 
were extracted from MALDI–MSI datasets (Figure  5A,B). 
Endogenous malonyl-CoA signal ([M+H] + 854.1  ± 0.2  Da) in 
A549 cells demonstrated a four-fold change (FC: treated cells/
vehicle control) increase, demonstrating the possibility to use 
MALDI–MSI as a relative quantitative readout for cell-based 
compound profiling on DMA–ITO slides (Figure  5A). The 
IC50 value (marked with an asterisk) derived from this concen-
tration-response curve matches previously described results 
obtained with a mechanistic MALDI–TOF–MS cell-based assay 
Table 1. Seeding densities and volumes used for different array formats to keep the cell density per area (mm2) constant. Seeding volumes were 5 µL, 
150 nL, and 40 nL for 3 mm circular, 1 mm squared, and 0.5 mm squared array spots, respectively.
No. cells/spot Seeding density [cells mL−1] No. cells/spot Seeding density [cells mL−1] No. cells/spot Seeding density [cells mL−1]
[Cells mm−2] Array size: Ø 3 mm Array size: 1 mm Array size: 0.5 mm
707 5000 1 × 106 555 3.7 × 106 138 3.5 × 106
354 2500 5 × 105 277 1.8 × 106 70 1.7 × 106
141 1000 2 × 105 111 7.5 × 105 28 6.9 × 105
71 500 1 × 105 55 3.7 × 105 14 3.5 × 105
14 100 2 × 104 11 7.5 × 104 3 6.9 x 104
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of FASN inhibition using standard 384-well steel targets.[15] 
When plotted against inhibitor concentration, the normal-
ized intensity fold-change for an endogenous lipid (tentatively 
assigned phosphatidylcholine: PC (34:1) ([M+H]+ m/z 760.6  ± 
0.2  Da)) showed a moderately decreasing concentration-
response curve. This may indicate successful inhibition of de 
novo synthesis of fatty acids and functionally coupled inhibi-
tion of phospholipid synthesis (Figure 5B). The corresponding 
MALDI–MSI ion image (Figure  5C) shows the spatial signal 
distribution of presumably PC (34:1) in red, and malonyl-CoA 
in green. The spatial distribution of analytes of interest was 
visualized as ion intensity maps. The triplicates of the experi-
ment shown in Figure 5C demonstrate both perfect reproduc-
ibility of the method, and homogeneity of the spot size and 
shape owing to the hydrophilic-superhydrophobic borders.
3. Conclusions
In this study we have demonstrated hyphenation of two 
powerful technologies: droplet microarrays (DMA) and 
MALDI mass spectrometry imaging (MALDI–MSI) to create 
a DMA–MSI platform. By combining these technologies, we 
demonstrate the potential for miniaturized high-throughput 
cell screening with the biochemical analysis capabilities of 
mass spectrometry in a single platform. We have established 
a method for the creation of hydrophilic–superhydrophobic 
microarrays on conductive ITO slides, showing that confine-
ment of droplets by superhydrophobic borders improves 
robustness of the matrix application, facilitates spot posi-
tioning and increases signal homogeneity and sensitivity of 
the detection. Using this platform, we have demonstrated 
highly miniaturized (down to 40  nL and 10  cells per spot) 
MALDI–TOF–MS cell-based screening assays with label-free 
quantitative readout using MALDI–MSI. Using concentra-
tion-response profiling of the fatty acid synthase inhibitor 
GSK2194069 in A549 lung cancer cells as an example, IC50 
curves were determined based on the chemical composition 
of the cell surface. The uniqueness of the DMA–MSI platform 
for cell-based assays lies in the possibility to perform both 
optical microscopy and mass-spectrometric readouts using the 
same cell microarray with a minimum number of preparative 
steps, while at the same time maximizing ion yield by using a 
conductive substrate.
Figure 4. Proof of Principle of New DMA-MSI Platform to Analyze Inhibition of FASN Based on MSI of Cellular Malonyl-CoA Accumulation as Response 
Marker in A549 Cancer Cells. A) Chemical structure of GSK2194069, a selective fatty acid synthase (FASN) inhibitor that leads to intracellular accumula-
tion of the FASN substrate malonyl-Coenzyme (malonyl-CoA). B–D) A549 cells were seeded in assay medium in 3 mm droplet microarrays on indium 
tin oxide (DMA-ITO) and were treated for 24 h with two high concentrations of GSK2194069 or dimethyl sulfoxide (DMSO) as control (0 µm FASN 
inhibitor). Matrix-assisted laser desorption/ionization-time-of-flight (MALDI-TOF) mass spectra were pre-processed using SCiLS Lab and TIC-normal-
ized ion intensities are shown. B) The spatial distribution of malonyl-CoA (m/z 854.1; yellow) was visualized as ion intensity map using flexImaging 
software. The spatial signal distribution of the tentative membrane lipid (phosphatidylcholine; PC 34:1) is presented in gray for comparison. C) Original 
TIC-normalized spectra of m/z 854.1 from randomly chosen single signal-bearing pixels of inhibitor-treated and untreated array positions analyzed in 
flexAnalysis. D) Malonyl-CoA is significantly increased in GSK20194069-treated cells compared to untreated cells. The mean ion intensity of m/z 854.1 
from five technical replicates (n = 5) within 3 mm droplet array was plotted against inhibitor concentration and expressed as median ± interquartile 
range (1st and 3rd quartile) by Tukey boxplot with whiskers representing the minimum and maximum values. For the non-normally distributed data 
one-way Kruskal–Wallis testing followed by Dunn´s Multiple Comparison post-hoc test was carried out across groups (* p ≤ 0.05 and ** p ≤ 0.01).
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The DMA–MSI platform developed here offers several 
advantages compared with other technologies:
•	 Label-free readout while obtaining greater amounts of mole-
cular information for each pixel (namely one mass spectrum 
per pixel);
•	 Direct cell culture on DMA–ITO slides, enabling microscopy 
and MALDI–TOF–MSI on one array;
•	 Miniaturization of cell assays compared with standard MAL-
DI target plates, resulting in higher spot density (DMA spot 
size ≤ 0.5 mm);
•	 Analysis of minute numbers of cells per spot, down to single-
cell level;
•	 A faster overall sample preparation workflow;
•	 Potential for customization – the porous, cell-supporting coating 
can be potentially applied to various conductive substrates,[26] 
enabling adaptation of different cell culture formats.[27]
Thus, the DMA–MSI platform has great potential for the 
field of high-throughput cell screening, drug screening, metab-
olomics, for basic research and drug discovery.
4. Experimental Section
Materials: All reagents were of HPLC grade. Milli-Q water (ddH2O; 
Millipore) was prepared in-house. Acetonitrile (ACN), trifluoroacetic 
acid (TFA) and A549 cells, a human non-small-cell lung cancer cell 
line, were purchased from Merck (Darmstadt, Germany). Cell culture-
grade dimethyl sulfoxide (DMSO), ammonium formate, and penicillin-
streptomycin as well as the FASN inhibitor GSK2194069 were obtained 
from Sigma Aldrich (Munich, Germany). A stock solution of 10  mm 
malonyl-CoA (Sigma-Aldrich) dissolved in ddH20 was stored at −80 °C. 
RPMI 1640 with stable glutamine (VWR International, Darmstadt, 
Germany) was used as cell culture medium. Fetal bovine serum (FBS) 
Figure 5. Quantitative Analysis of the GSK20194069 Drug Response in A549 Cancer Cells on the DMA-MSI platform. A–C) Concentration-response 
curve of total ion count (TIC)-normalized extracted features (m/z 854.1 for malonyl-Coenzyme A (malonyl-CoA) and m/z 760.6 tentatively for protonated 
phosphatidylcholine (PC, 34:1) from the matrix-assisted laser desorption/ionization-mass spectrometry imaging (MALDI MSI) dataset were plotted 
using GraphPad Prism (n = 3 technical replicates per concentration within 3 mm droplet array). A549 cells were seeded in assay medium onto a droplet 
microarray-indium tin oxide (DMA-ITO) slide for 18 h and incubated for 24 h with various concentrations of GSK2194069. MALDI-TOF mass spectra 
were pre-processed using SCiLS Lab and TIC-normalized ion intensities are shown. A) The fold-change (treated cells / dimethyl sulfoxide [DMSO] 
control, n = 3) of endogenous malonyl-CoA ion intensity ([M+H] + m/z 854.1 ± 0.2 Da) in A549 cells was plotted against inhibitor concentration. The 
IC50 is marked by an asterisk and derived from this concentration-response curve, matches previously described results.[9] Data were presented as 
mean ± standard deviation (SD) from three technical replicates per concentration within 3 mm droplet array. B) The fold-change (treated cells / DMSO 
control, n = 3) of the tentatively assigned PC (34:1) ([M+H] + 760.6 ± 0.2 Da) was plotted against inhibitor concentration and shows a moderate decrease 
that may be attributed to inhibition of de novo synthesis of fatty acids. Data were presented as mean ± standard deviation (SD) from three technical 
replicates per concentration within 3 mm droplet array C) Corresponding MALDI-MSI ion image (visualized using flexImaging software) shows the 
spatial signal distribution of PC(34:1) in red and malonyl-CoA in green.
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and charcoal-stripped FBS for assay medium were from Life Technologies 
(Darmstadt, Germany). For MALDI-MSI, conductive indium tin oxide 
(ITO)-coated glass slides were purchased from Bruker Daltonics 
(Bremen, Germany) and the MALDI matrix 2,5-dihyroxybenzoic acid 
(DHB) from Alfa Aesar (Karlsruhe, Germany). Porcine brain total lipid 
extract was purchased from Avanti Polar Lipids (Alabama, USA).
Preparation of Droplet Microarrays on Conductive Indium tin Oxide 
(ITO) Slides: The customized droplet microarray slides (25  mm × 
75 mm) were fabricated by Aquarray GmbH (Eggenstein–Leopoldshafen, 
Germany). The microarray slides were prepared directly on conductive 
ITO glass slides, and referred to as DMA-ITO slides. Briefly, indium-tin 
oxide (ITO) glass slides were structured to create nanoporous layer 
important for increasing both hydrophilicity and hydrophobicity, as well 
as enhance cell growth, as it was shown that roughness in combination 
with chemical surface modification tends to enhance cell growth on 
substrates, especially that of certain primary cells[28]. The surface hydroxy 
groups were silanized to introduce double bonds, which were then 
functionalized photochemically using either hydrophilic or hydrophobic 
(fluorinated) thiols to result in highly hydrophilic and superhydrophobic 
regions, respectively. The coating adhered well and homogenously 
onto the ITO surface while being thin enough to avoid insulation of 
the conductive surface.[29] Average ion intensities of various brain 
total lipid extract lipids on ITO and DMA-ITO were indistinguishable, 
suggesting comparable conductance of the two coatings. To prove if 
the conductivity of the ITO glass slide did not change due to additional 
nanorough layer by spin coating the resistance was always checked with 
a digital multimeter (Voltcraft, Hirschau, Germany) in Ω  cm−2 prior 
cell culturing. Three different formats of DMA-ITO were used: arrays of 
5 × 16 spots with side length of 3 mm; 14 × 48 spots with side length of 
1 mm and 28 × 84 spots with side length of 0.5 mm.
Cell Culture on DMA-ITO Slides: A549 cells were pre-cultured in T75 
flasks with RPMI-1640 supplemented with glutamine, 10% (v/v) FBS 
and 1% (v/v) penicillin/streptomycin at 37  °C at 5% CO2. 10% v/v 
fetal bovine serum (FBS) and 1% v/v penicillin/streptomycin (P/S) at 
37  °C with 5% CO2 atmosphere. For the analysis of miniaturized cell-
based assays, A549 cells were seeded at various densities ranging from 
707 to 14 cells/mm2 on three different DMA-ITO slides with array spot 
sizes of 3, 1, and 0.5  mm. The total cell number per array spot was 
adjusted as listed in Table  1 in order to keep cell density (cells/mm2) 
comparable. The following culture volumes were used: 5 µL, 150 nL, and 
40 nL for DMA-ITO with spot sizes of 3, 1, and 0.5  mm, respectively. 
Cells were seeded onto DMA–ITO slides using low volume dispenser 
I-DOT (Dispendix GmbH, Stuttgart, Germany). Afterwards slides were 
incubated overnight at 37  °C at 5% CO2. Subsequently, slides were 
washed three times with cold 150  mm ammonium formate at pH 7.4. 
Until MALDI MSI analysis, slides were frozen on dry-ice and stored at 
−80 °C.
FASN Inhibition Cell Assay on DMA-MSI Platform: One day prior 
to inhibitor treatment, cells were resuspended in concentration 
6.3  ×  105  cells mL−1 cell culture medium supplemented with 10% v/v 
charcoal stripped FBS (assay medium). 8  µL of the cell suspension 
was seeded per spot on the DMA-ITO slides with 3 mm spot sizes and 
incubated overnight for 18 h at 37 °C at 5% CO2. On the following day, 
cells were treated for 24  h with GSK2194069. To keep the final DMSO 
concentration of 0.33% (vol.%) in the assay constant, a ten-step dilution 
series of 10  mm GSK2194069 in DMSO stock solution was performed 
in DMSO at ratio of 1: 3.3, obtaining the following concentrations: 
3.2, 1.0, 0.3, 0.1, 0.03, 0.01 mm, 3.2, 1.0, 0.3, and 0.1 µm. Each of these 
concentrations was subsequently diluted with assay medium at a ratio 
of 1:150 (one volume diluted 150-fold in assay medium), obtaining the 
following concentrations: 21.1, 6.7, 2.1, 0.67, 0.21, 0.067, 0.021, 0.0067, 
0.0021 µm, 0.67 nm. Finally, for all concentrations of FASN inhibitor, one 
volume of inhibitor (8 µL) was added to one volume (8 µL) of cell culture 
droplets. Final inhibitor concentrations were 10.5, 3.3, 1.1, 0.33, 0.11, 
0.033, 0.011 µm, 3.3, 1.1, 0.33 nm and 0.33% DMSO as a vehicle control 
in a total volume of 16 µL on 3 mm Droplet array (DMA-ITO). After 24 
h, slides were washed three times with ice-cold 150  mm ammonium 
formate at pH 7.4 and were subsequently air-dried.
Cell Viability Assay: Live/dead staining of cells cultured on DMA-ITO 
slides was performed by dispensing 2.5 µL, 50 nL, and 14 nL of solution 
containing 1.5 µg mL−1 Calcein AM (Thermo Scientific) and 1.5 µg mL−1 
propidium iodide (PI) (Invitrogen, Merelbeke, Belgium) in Dulbecco’s 
PBS to the droplets on 3, 1, and 0.5 mm spots, respectively, using low 
volume dispenser I-DOT (Dispendix GmbH, Stuttgart, Germany). Cells 
were incubated for 15 min in cell culture incubator and then imaged using 
Keyence BZ-9000 microscope (KEYENCE, Osaka, Japan). The number of 
Calcein-positive (live) and PI-positive (dead) cells was estimated using 
ImageJ software, and viability of cells was calculated as a ratio of number 
of live cells to total number of cells (sum of live cells and dead cells).
MALDI-TOF Mass Spectrometry Imaging: For MALDI MSI, washed 
DMA-ITO cell arrays were air-dried or vacuum-dried after freezing for 
15 min at RT. DHB matrix was prepared at a concentration of 60 mg mL−1 
in ACN/ddH2O/TFA (50/49.9/0.1; v/v/v) unless indicated otherwise. 
Matrix deposition on cells grown on DMA-ITO slides was performed 
by spray-coating using a HTX TM 5-sprayer (HTX Technologies, LLC, 
Chapel Hill, NC, USA): Briefly, five layers were sprayed at 100 µL min−1 
matrix flow rate and 1200  mm min−1 spray-head velocity with 3  mm 
distance between sprayed lines (CC pattern). Spray nozzle height was 
set to 40 mm from the ITO slide and temperature was heated to 75 °C 
with a pressure of 10  psi and 2 L min−1 of gas flow rate. MALDI-MSI 
experiments were performed using a rapifleX MALDI-TOF mass 
spectrometer (Bruker Daltonics, Bremen, Germany) equipped with a 
10 kHz smartbeam 3D laser. Data was acquired in reflector positive ion 
mode within an m/z range of 500–1200 using a raster width of 50 µm 
for the 3  mm DMA or 25  µm for the 1- and 0.5  mm DMA employing 
ftmsControl 4.1.8 and flexImaging 5.0.89.0 softwares (Bruker Daltonics). 
Focus and laser power settings were optimized with a sampling rate of 
1.25 for 50 or 25 µm pixel size with 200 shots per pixel. FASN inhibition 
analysis was executed at a lateral step-size of 100  µm over a mass 
range of m/z 400–1000 summing up 250 laser shots per pixel with a 
sampling rate of 1.25. External quadratic calibration of the rapifleX 
was typically performed using porcine brain total lipid extract, but a 
mixture of the lysophosphatidylcholine LPC(18:1) ([M+H]+ 522.355), the 
phosphatidylcholine, PC(34:1) ([M+H]+ 760.585 and [M+K]+ 798.541) and 
malonyl-CoA ([M+H]+ 854.123) for the FASN inhibition assay.
Pre-Processing and Visualization of MALDI MS Imaging Data: The 
pre-processing of MALDI imaging data was executed using the SCiLS 
Lab 2019 software (Bruker Daltonics). Thus, baseline subtraction was 
performed using the top-hat algorithm and all mass spectra were divided 
by their Total Ion Count (TIC), so that all spectra in a dataset have the 
same integrated area under the spectrum. The spatial distribution 
of a selected mass to charge ratio (m/z) of an ionized molecule was 
visualized as TIC-normalized ion intensity map using SCiLS Lab 2019 or 
flexImaging software version 5.0 from Bruker Daltonics.
For data comparison in Figure  2D, TIC-normalized mean spectra 
of regions-of-interest (ROI) drawn in SCiLS Lab were exported into 
mMass (V5.5.0)[30] in order to flip spectra vertically to detect any 
differences between those two mass spectra (“butterfly plot”). For an 
automated and unsupervised segmentation analysis in Figure  3B, all 
TIC-normalized mass spectra were analyzed in SCiLS Lab using m/z 
value 760.6 ± 0.1 Da by bisecting k-means algorithm and the correlation 
distance metric without denoising. In Figures  3E and  4C, original TIC-
normalized spectra of specific m/z-values from randomly chosen single 
signal-bearing pixels were extracted and analyzed with flexAnalysis 3.4 
software (Bruker Daltonics) or mMass. Peak quality parameters were 
signal to noise threshold (S/N) = 6 and peak width  =  0.1  Da at 75% 
peak height. Original mass spectra were externally re-calibrated in 
flexAnalysis or in mMass. In Figure 5A,B, concentration-response curves 
from the FASN inhibition assay were plotted with GraphPad Prism 
software version 5.0 (GraphPad). Therefore, the mean ion intensity of 
TIC-normalized spectra from m/z- values 854.1 and 760.6 ± 0.2 Da were 
extracted from ROIs drawn in SCiLS Lab around the 3 mm droplet spots 
and exported into GraphPad Prism. For each of these m/z values relative 
quantification was performed by determining the fold-change (FC) of 
ion intensity from inhibitor-treated samples versus the vehicle DMSO 
control. The fold change was plotted against inhibitor concentration. 
Adv. Biology 2021, 2000279
www.advancedsciencenews.com www.advanced-bio.com
2000279 (10 of 11) © 2021 The Authors. Advanced Biology published by Wiley-VCH GmbH
Data were presented as mean ± standard deviation (SD) from three 
technical replicates per concentration within 3 mm droplet array.
Statistical Analysis: In order to demonstrate utility of the DMA-MSI 
platform for a FASN inhibitor assay, the MALDI imaging data was pre-
processed in SCiLS Lab as described above. For Figure 4D the intensity 
of the Malonyl-CoA ion signal (m/z 854.1 ± 0.2 Da) was extracted from 
the TIC-normalized average spectra from ROIs drawn in SCiLS Lab 
around the 3 mm droplet spots. Extracted signals for all tested inhibitor 
concentrations and vehicle control were imported into GraphPad Prism 
for statistical analysis. Therefore, the mean ion intensity of m/z 854.1 
from five technical replicates was plotted against inhibitor concentration 
as median ± interquartile range by Tukey boxplot. For the non-normally 
distributed data one-way Kruskal-Wallis test was carried out across 
groups. Pairwise comparisons of ion intensity from inhibitor-treated 
samples versus the vehicle DMSO control were performed using 
Dunn´s Multiple Comparison post-hoc test and significant differences 
were reported as * p ≤ 0.05 and ** p ≤ 0.01.
Data presentation and sample size (n) for each analysis was indicated 
in the corresponding figure legend.
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